NYSE:NVTA

Stock Analysis Report

Executive Summary

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally.

Snowflake

Fundamentals

Excellent balance sheet with limited growth.

Risks

  • Invitae has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Invitae's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.1%

NYSE:NVTA

0.6%

US Biotechs

0.8%

US Market


1 Year Return

33.3%

NYSE:NVTA

-10.2%

US Biotechs

1.9%

US Market

NVTA outperformed the Biotechs industry which returned -9.7% over the past year.

NVTA outperformed the Market in United States of America which returned 2.1% over the past year.


Share holder returns

NVTAIndustryMarket
7 Day1.1%0.6%0.8%
30 Day-16.6%-0.8%3.4%
90 Day-0.3%-0.5%2.1%
1 Year33.3%33.3%-9.4%-10.2%4.2%1.9%
3 Year158.9%158.9%6.0%2.4%46.7%37.2%
5 Yearn/a5.0%-0.09%62.3%44.5%

Price Volatility Vs. Market

How volatile is Invitae's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Invitae undervalued based on future cash flows and its price relative to the stock market?

5.9x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Invitae to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Invitae to establish if it is available at substantial discount.


Price Based on Earnings

Invitae is loss making, we can't compare its value to the US Biotechs industry average.

Invitae is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Invitae, we can't assess if its growth is good value.


Price Based on Value of Assets

Invitae is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Invitae expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

22.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Invitae's revenue is expected to grow significantly at over 20% yearly.

Invitae is not considered high growth as it is expected to be loss making for the next 1-3 years.

Invitae's revenue growth is expected to exceed the United States of America market average.

Unable to compare Invitae's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Invitae's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Invitae will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Invitae performed over the past 5 years?

-21.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Invitae does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Invitae's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Invitae's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Invitae has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Invitae has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Invitae improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Invitae's financial position?


Financial Position Analysis

Invitae is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Invitae's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Invitae's level of debt (22%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (0% vs 22% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 3.8x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Invitae has sufficient cash runway for 2.3 years based on current free cash flow.

Invitae has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 7.5% each year.


Next Steps

Dividend

What is Invitae's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Invitae's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Invitae's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Invitae has not reported any payouts.

Unable to verify if Invitae's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Invitae has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Invitae's salary, the management and board of directors tenure and is there insider trading?

2.6yrs

Average management tenure


CEO

Sean George (45yo)

2.7yrs

Tenure

US$2,233,360

Compensation

Dr. Sean E. George, Ph.D. is the Co-Founder of InVitae Corporation and has been its President since August 2012. Dr. George has been Chief Executive Officer of InVitae Corporation since January 9, 2017 and ...


CEO Compensation Analysis

Sean's remuneration is lower than average for companies of similar size in United States of America.

Sean's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.6yrs

Average Tenure

53.5yo

Average Age

The tenure for the Invitae management team is about average.


Board Age and Tenure

5.7yrs

Average Tenure

55yo

Average Age

The tenure for the Invitae board of directors is about average.


Insider Trading

Invitae individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$128,41027 Aug 19
Geoffrey Crouse
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares5,000
Max PriceUS$25.68
SellUS$517,19321 Aug 19
Shelly Guyer
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares20,447
Max PriceUS$25.29
SellUS$537,88321 Aug 19
Lee Bendekgey
EntityIndividual
Role
Chief Operating Officer
Secretary & COO
Shares21,265
Max PriceUS$25.29
SellUS$517,19321 Aug 19
Robert Nussbaum
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares20,447
Max PriceUS$25.29
SellUS$413,76421 Aug 19
Sean George
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares16,358
Max PriceUS$25.29
SellUS$579,23921 Aug 19
Katherine Stueland
EntityIndividual
Role
Senior Key Executive
Chief Commercial Officer
Shares22,900
Max PriceUS$25.29
SellUS$345,59621 Aug 19
Thomas Brida
EntityIndividual
Role
Chief Legal Officer
General Counsel
Shares13,663
Max PriceUS$25.29
SellUS$117,89223 May 19
Katherine Stueland
EntityIndividual
Role
Senior Key Executive
Chief Commercial Officer
Shares6,474
Max PriceUS$18.21
SellUS$39,07923 May 19
Thomas Brida
EntityIndividual
Role
Chief Legal Officer
General Counsel
Shares2,146
Max PriceUS$18.21
SellUS$124,75723 May 19
Lee Bendekgey
EntityIndividual
Role
Chief Operating Officer
Secretary & COO
Shares6,851
Max PriceUS$18.21
SellUS$442,17523 May 19
Sean George
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares24,282
Max PriceUS$18.21
SellUS$100,39222 May 19
Shelly Guyer
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares5,513
Max PriceUS$18.21
SellUS$131,14822 May 19
Robert Nussbaum
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares7,202
Max PriceUS$18.21
SellUS$25,23018 Apr 19
Katherine Stueland
EntityIndividual
Role
Senior Key Executive
Chief Commercial Officer
Shares1,000
Max PriceUS$25.23
SellUS$135,00029 Nov 18
Eric Aguiar
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares10,000
Max PriceUS$13.50
SellUS$10,69520 Sep 18
Patricia Dumond
EntityIndividual
Shares645
Max PriceUS$16.67

Ownership Breakdown


Management Team

  • Lee Bendekgey (61yo)

    Secretary & COO

    • Tenure: 2.3yrs
    • Compensation: US$1.48m
  • Robert Nussbaum (69yo)

    Chief Medical Officer

    • Tenure: 4.1yrs
    • Compensation: US$802.74k
  • Shelly Guyer (59yo)

    Chief Financial Officer

    • Tenure: 2.3yrs
    • Compensation: US$1.40m
  • Katherine Stueland (43yo)

    Chief Commercial Officer

    • Tenure: 2.9yrs
    • Compensation: US$1.48m
  • Tom Brida (48yo)

    General Counsel

    • Tenure: 2.7yrs
  • Sean George (45yo)

    Co-Founder

    • Tenure: 2.7yrs
    • Compensation: US$2.23m
  • Michelle Fox

    Consultant

    • Tenure: 0yrs
  • Eric Olivares

    Head of Clinical Operations & Assay Development

    • Tenure: 2.6yrs
  • Alex Furman

    Executive Officer of Organizational Development

    • Tenure: 1.3yrs
  • Laura D'Angelo

    Head of Investor Relations

    • Tenure: 0yrs

Board Members

  • Eric Aguiar (57yo)

    Independent Director

    • Tenure: 9yrs
    • Compensation: US$96.27k
  • Christine Gorjanc (62yo)

    Independent Director

    • Tenure: 3.8yrs
    • Compensation: US$91.27k
  • Sean George (45yo)

    Co-Founder

    • Tenure: 2.7yrs
    • Compensation: US$2.23m
  • Geoff Crouse (48yo)

    Independent Director

    • Tenure: 7.5yrs
    • Compensation: US$96.27k
  • Chitra Nayak (55yo)

    Independent Director

    • Tenure: 1yrs
    • Compensation: US$164.89k
  • Elizabeth McNally

    Member of Advisory Board

    • Tenure: 0yrs

Company Information

Invitae Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Invitae Corporation
  • Ticker: NVTA
  • Exchange: NYSE
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.045b
  • Shares outstanding: 95.18m
  • Website: https://www.invitae.com

Number of Employees


Location

  • Invitae Corporation
  • 1400 16th Street
  • San Francisco
  • California
  • 94103
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NVTANYSE (New York Stock Exchange)YesCommon StockUSUSDFeb 2015
IV8DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2015
0JDBLSE (London Stock Exchange)YesCommon StockGBUSDFeb 2015

Biography

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 01:16
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.